

Discussion Topic for the Committee

- Please discuss possible changes to the antigen composition of future seasonal influenza vaccines:
 - The advantages versus the disadvantages of retaining the B/Yamagata lineage component in the quadrivalent influenza vaccine
 - The timing for possible removal of the B/Yamagata lineage component from the current quadrivalent formulation
 - The opportunities and challenges for alternative vaccine composition formulations and the data needed to support such changes

Voting Questions for the Committee

1. Does the committee recommend excluding the B/Yamagata lineage antigen component from quadrivalent influenza vaccines as soon as possible
2. For the composition of egg-based trivalent 2024 SH formulations of influenza vaccines, does the committee recommend:
 - Inclusion of an A/Victoria/4897/2022 (H1N1)pdm09-like virus;
 - Inclusion of an A/Thailand/8/2022 (H3N2)-like virus; and
 - Inclusion of a B/Austria/1359417/2021 (B/Victoria lineage)-like virus
3. For quadrivalent 2024 SH formulations of influenza vaccines, does the committee recommend:
 - Inclusion of a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus as the 2nd influenza B strain in the vaccine